InterVenn harnesses the heretofore elusive power of glycoproteomics for the discovery and development of high ac-curacy novel diagnostic, predictive, and prognostic markers as well as for discovery and validation of uniquely powerful new drug targets. We have developed a uniquely powerful, mass-spectrometry/AI-neural-network-driven platform for the analysis of the glycoproteome at a level of resolution, accurate quantification, and highly scalable throughput currently not available anywhere else. Using this platform, the company is pioneering the actionable application of glycoproteomics in both diagnostic and therapeutic fields; currently having been able to generate highly accurate tools for the prediction of a number of oncologic as well as other indications; and is expanding the deployment of the platform for highly innovative target discovery and validation approaches with a number of key partners.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Ovarian Cancer Prediction
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):